Third COVID-19 vaccine dose for people with multiple sclerosis who did not seroconvert following two doses of BBIBP-CorV (Sinopharm) inactivated vaccine: A pilot study on safety and immunogenicity.

Nahad Sedaghat,Masoud Etemadifar,Noushin Lotfi,Farnaz Sayahi,Ahmad Chitsaz,Mehri Salari,Alireza Ghasemi Movaghar

Frontiers in immunology（2023）

引用 0|浏览9

暂无评分

摘要

This preliminary pilot study highlights the need for further research to determine the optimal COVID-19 third dose vaccination strategy for pwMS living in areas where BBIBP-CorV vaccine has been used.

查看译文

关键词

BBIBP-CorV,COVID-19,disease-modifying therapies (DMTs),multiple sclerosis,vaccine immunogenicity

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要